The Role of Nasal Breathing for Perfomance in Elite Athletes.

NCT06480071 | Completed

• 1 other identifier: Dnr 2020-03808
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This study investigates the contribution of nasal breathing to the performance during aerobic and anaerobic heavy exercise in 12 male elite cyclists. In a ramp test on a mechanically braked cycle ergometer (Monark LT2, Varberg, Sweden) VO2 max, heart rate, respiratory frequency, intranasal geometry and nasal airflow resitance as well as blood lactate and glucose was measured at each step of the ramp test and after a maximum exhaust test. Nasal breathing was randomized to three sepratae tests, normal open nose, decongested nose with oxymetazoline 0.5mg/ml, 2 sprays each nostril and with a nose clip. The study showed that in the test with the nose clip, mean blood lactate was significantly lower.

Conditions

Breathing, Mouth

Outcome Measures

Primary Outcomes (3)

• VO2 max

  maximum oxygen upptake during exrecise

  7 minutes per cycle

• blood lactate

  lactic acid, a cmponent produced during anaerobic heavy exercise

  7 minutes per cycle

• Effect

  Watt effect generated during exercise

  7 minutes per cycle

Secondary Outcomes (2)

• HR

  7 minutes per cycle

• nasal air flow resistance

  7 minutes per cycle

Study Arms (1)

Nasal decongestion during exercise

EXPERIMENTAL

Nasal decongestion with oxymetazomin nasal spray 0.05% 2 sprays each nostril 10 minutes before the exercise test

Drug: Oxymetazoline, 0.05% Nasal Spray

Interventions

Oxymetazoline, 0.05% Nasal Spray DRUG

2 sprays each nostril before the excercise test.

Nasal decongestion during exercise

Eligibility Criteria

• Age: 18 Years - 40 Years
• Gender Eligibility Details: To increase standardisation regarding physical performance only one sex was included in the study
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• male subjects
• age 18-40
• elite cyclists or Triathlon athletes
• minimum VO2max of ≥65 ml/min/kg on pretest.

You may not qualify if:

• non-male
• \<18\>40 years of age
• non-elite cyclists or Triathlon athletes
• less than VO2max of ≥65 ml/min/kg on pretest

Sponsors & Collaborators

• Sahlgrenska University Hospital: lead

Study Sites (1)

Department of ENT Sahlgrenska University Hospital

Gothenburg, 41345, Sweden

Location

MeSH Terms

Conditions

Mouth Breathing

Interventions

Oxymetazoline; Nasal Sprays

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Aerosols; Colloids; Complex Mixtures; Dosage Forms; Pharmaceutical Preparations

Study Officials

• Johan Hellgren, MD, PhD, Professor

  Department of ENT Sahlgrenska University Hospital Sweden

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: The nasal mucosa was decongested with oxymetazoline nasal spray 0.5mg/ml 2 sprays eacg nostril to achieve maximum nasal decongestion and to investigate if this promotes the physical performance during heavey exercise.

Study Record Dates

• First Submitted: June 24, 2024
• First Posted: June 28, 2024
• Study Start: January 13, 2022
• Primary Completion: March 17, 2022
• Study Completion: March 17, 2022
• Last Updated: July 1, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)